NewsEvents

Your Yourlocation: Home > Multicentre randomized controlled clinical trial of domestic tiotropium bromide(136310-93-5) powder in the treatment of chronic obstructive pulmonary disease

To evaluate the efficacy and safety of domestic tiotropium bromide(136310-93-5) powder in patients with chronic obstructive pulmonary disease (COPD) in China. Studies have shown that domestic tiotropium bromide(136310-93-5) powder for the improvement of COPD patients with pulmonary function and clinical symptoms, safe and effective, and its long-term efficacy to be further verified. The article published on "Journal of Sichuan University (Medical Sciences)".

The control group (n = 111) was given QDI of ipratropium bromide aerosol 40 μg inhaled QID, the course of treatment (n = 109) was given QDI of tiotropium bromide(136310-93-5) dry powder 18 μg in the test group (n = 109) 4 weeks, the indicators of pulmonary function, clinical symptoms and safety.

The forced expiratory volume (FEV1) at 30 min and 3 h after the first dose was higher than that at baseline (P <0.05). The FEV1 and FVC of the experimental group and control group were significantly higher than those of the control group (P <0.05). The scores of COPD in the experimental group and the control group were lower than those in the baseline and the experimental group was better than that in the control group (P <0.05). There was no statistically significant difference between the two groups in the amount of albuterol aerosol sprayed during the treatment. The incidence of adverse reactions was (22.02%) and (15.32%) in the control group (P = 0.23).

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved